13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01767493 (ClinicalTrials.gov) | November 2012 | 13/12/2012 | Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients | An Open-label, Non-randomized Study to Evaluate the Feasibility of [18F]Florbetapir Positron Emission Tomography (PET) for Assessment of Demyelination in Patients With Relapsing Remitting Multiple Sclerosis | Multiple Sclerosis | Drug: [18F]Florbetapir PET imaging | Institute for Neurodegenerative Disorders | Biogen | Completed | 18 Years | 60 Years | All | 19 | Phase 4 | United States |